CinFina Pharma Begins Phase 1 Trial For Obesity Drug CIN-110

CinFina Pharma, part of the CinRx portfolio and focused on developing impactful treatments for obesity and metabolic disorders, has launched the Phase 1 Multiple Ascending Dose (MAD) clinical trial for CIN-110, a novel and highly selective PYY3-36 analog aimed at treating obesity. This trial is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CIN-110 in obese adults. The MAD trial's initiation is based on positive results from the ongoing Single Ascending Dose (SAD) study, where CIN-110 demonstrated good tolerability and significant reductions in both caloric intake and body weight. The SAD study outcomes will guide dosing strategies for the current MAD trial.

Mary Bond, M.S., M.B.A., Chief Translational Science Officer of CinRx Pharma remarked, “To date, CIN-110 has demonstrated very strong safety and pharmacokinetic profiles in its single dose study, as well as encouraging pharmacodynamic data. We are excited to see this promising asset advance into this next clinical assessment where we will gain an even greater understanding of its potential to provide a safe and effective obesity treatment option for physicians and their patients.”

CIN-110, a powerful and highly selective PYY3-36 analog with an extended half-life, shows promise as a well-tolerated treatment option, potentially avoiding the severe nausea and vomiting seen in earlier PYY-based therapies. PYY3-36, a naturally occurring hormone released by endocrine L-cells in the gut in response to food—especially fat—acts as a selective agonist of the neuropeptide Y2 receptor (Y2R), effectively decreasing food intake by curbing appetite.

The multiple ascending dose (MAD) study is a randomized, placebo-controlled clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of subcutaneously (SC) administered CIN-110 in obese individuals over a 12-week period. Participants, both male and female, aged 18-55, have a body mass index ranging from 30.0 to 44.9 kg/m². The trial will feature several cohorts, each consisting of 12 subjects, randomized in a 3:1 ratio to receive either SC CIN-110 or a matching placebo.